In addition, we observed noticeably higher numbers of OVA-specific CD8+ T cells in pooled tumor-draining lymph node samples from PeptiCRAd VALO-mD901-OVA-treated mice compared to mock- or PeptiCRAd Ad5/3-D24-OVA-treated mice (Figure 4B). The gene discussed is CD8A; the disease is neoplasm.